Jason Haas insider trades: Ligand Pharmaceuticals (LGND) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | LGND | ↓ Sell | 7,138 | $292.81 | $2.1M | Direct | Aug 14, 2026 (2d) |
| Jun 12, 2026 | LGND | ↓ Sell | 6,461 | $255.58 | $1.7M | Direct | Jun 15, 2026 (3d) |
| May 8, 2026 | ODTX | ↑ Buy | 1,000 | $20.00 | $20K | Direct | May 11, 2026 (3d) |
| Nov 18, 2024 | SYRS | ↓ Sell | 137,803 | $0.21 | $29K | Direct | Nov 20, 2024 (2d) |
| Sep 12, 2024 | SYRS | ↑ Buy | 100,000 | $1.61 | $161K | Direct | Sep 12, 2024 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LGND insiders
Open-market trades in the last 12 months
About Jason Haas's insider trades
Jason Haas is a director at Ligand Pharmaceuticals (LGND). Since Sep 12, 2024, Jason has reported 2 open-market purchases worth $181K and 3 sales worth $3.8M on SEC Form 4. In the last 12 months: 1 buy ($20K) and 2 sales ($3.7M).
Their filings also include grants and awards (9 filings), option exercises (6 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.